Company: PTPI
Filing Date: 2025-02-13
Form Type: S-1/A
Source: 0001410578-25-000122
Chunk: 271

Company: Petros Pharmaceuticals, Inc.
Filing Date: 2025-02-13
Form: S-1/A
Chunk 271
---
 in the consolidated statements of operations. As of September 30, 2024, there is unrecognized stock-based compensation expense (excluding performance awards). Stock-based compensation expense recognized for the three months ended September 30, 2024, and 2023 was $ and $, respectively.

F-45

11) Common Stock Warrants

The following is a summary of warrants for the nine months ended September 30, 2024:

| ​                                                        
 ​                                                        
 ​                                                        
 ​                                                        
 ​                                                        | ​ 
 ​ 
 ​ 
 ​ |                  ​ 
                  ​ 
                  ​ 
                  ​ 
 Number of Warrants | ​ 
 ​ 
 ​ 
 ​ | ​                
 ​                
 ​                
 Weighted-Average 
 Exercise Price   |      ​ 
      ​ 
      ​ | ​ 
 ​ 
 ​ 
 ​ |                ​ 
                ​ 
                ​ 
        Remaining 
 Contractual Term | ​ 
 ​ 
 ​ 
 ​ | ​           
 Aggregate   
 Intrinsic   
 Value ($ in 
 thousands)  | ​ |
|:---------------------------------------------------------|:--|-------------------:|:--|:-----------------|-------:|:--|-----------------:|:--|:------------|:--|
| Warrants outstanding - December 31, 2023                 |   |          8,203,839 | ​ | $                |  14.93 | ​ |              4.3 | ​ | $           | — |
| Warrants issued                                          |   |                  — | ​ | ​                |      — | ​ |                — | ​ | ​           | — |
| Warrants exercised                                       |   |                  — | ​ | ​                |      — | ​ |                — | ​ | ​           | — |
| Warrants expired                                         |   |            -15,097 | ​ | ​                | 252.53 | ​ |                — | ​ | ​           | — |
| Warrants outstanding and exercisable- September 30, 2024 |   |          8,188,742 | ​ | $                |  14.49 | ​ |              3.5 | ​ | $           | — |

12) Dilutive convertible securities

The following table summarizes the potentially dilutive securities convertible into common shares that were excluded from the calculation of diluted net income (loss) per share because their inclusion would have been antidilutive:

| ​                                    | ​ |                          ​ | ​ |          ​ | ​ |                         ​